EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein

Poul Henning Jensen, Michael G Schlossmacher, Leonidas Stefanis iD

Movement Disorders · 2023

DOI: 10.1002/mds.29318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2023. Verfasst von Poul Henning Jensen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and DANDRITE, Danish Research Institute of Translational Neuroscience, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two recent, high‐profile manuscripts reported negative results with two parallel approaches of passive immunization targeting α‐synuclein in a population of patients with early Parkinson's disease (PD). These phase II studies failed to show a bona fide disease‐modifying neuroprotective effect on PD progression, despite the evidence that these antibodies effectively bind native α‐synuclein in human serum. Here, we discuss the possible reasons that could help explain the lack of clinical efficacy. In particular, we highlight (1) the wealth of evidence supporting the notion of α‐synuclein as a valid therapeutic target; (2) the lack of evidence of target engagement in the aforementioned studies, especially of the elusive oligomeric species, the likely culprits in disease pathogenesis and/or its propagation; (3) the limitations, especially in terms of timing passive immunization, of preclinical models, where the same α‐synuclein antibodies succeeded in mitigating disease manifestations; (4) the consideration of possibly intervening at an even earlier stage of disease in future trials; and (5) the multitude of strategies beyond passive immunization that could be used to combat α‐synuclein‐mediated neurodegeneration, if in the end the current approach is not fruitful. Overall, our perception is that converging developments in the field, among them novel bioassays and biomarkers, improved cellular and animal models and objective measurements of motor activities integrated into clinical trials, if further optimized, will gradually move the momentum of the field forward. This, to better test the concept of whether α‐synuclein‐targeting therapies can indeed deliver the ”holy grail” of neuroprotection to the benefit of the PD community. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinParkinson DiseaseAnimalsHumansAntibodiesBiomarkersTreatment Outcome

Stichwörter der Autor:innen

aggregationimmunotherapyoligomerssynucleinopathytherapeutics

Substanzen

alpha-SynucleinAntibodiesBiomarkersSNCA protein, human

Autor:innen und Institutionen

  • Department of Biomedicine and DANDRITE, Danish Research Institute of Translational Neuroscience, Aarhus University, Aarhus, Denmark.
  • Program in Neuroscience and Division of Neurology, The Ottawa Hospital, University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario, Canada.
  • First Department of Neurology, National and Kapodistrian University of Athens Medical School and Laboratory of Neurodegenerative Diseases, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

ORCID-Profile: Leonidas Stefanis

Zitieren

APA

Jensen, P. H., Schlossmacher, M. G., & Stefanis, L. (2023). Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein. Movement Disorders. https://doi.org/10.1002/mds.29318

Vancouver

Jensen PH, Schlossmacher MG, Stefanis L. Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein. Movement Disorders. 2023. doi:10.1002/mds.29318

BibTeX
@article{Jensen2023,
  author = {Jensen, Poul Henning and Schlossmacher, Michael G and Stefanis, Leonidas},
  title = {Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein},
  journal = {Movement Disorders},
  year = {2023},
  doi = {10.1002/mds.29318}
}
Kostenlos starten →